Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells

By M. Gnecchi, Huamei He, Olin D. Liang, L. Melo, F. Morello, H. Mu, N. Noiseux, Lunan Zhang, R. Pratt, J. Ingwall and 1 more. Nature Medicine, 2005

1,699 citations recorded by the source corpus.

Subfields: Biomaterials, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/44630cdb51f90c7da3e39355e71f3057e7ea53ee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. J. Karp
2. H. Ruskoaho
3. Virpi Talman

In Genetics

1. Charles E. Murry
2. J. Karp

In Surgery

1. Charles E. Murry
2. M. Laflamme
3. J. Karp
4. Nikolaos G. Frangogiannis
5. H. Ruskoaho
6. Virpi Talman
7. G. Keller

Citations in the corpus

• Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease (2012, background): “Please refer to the publisher's site for terms of use.”
• Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. (2010, background): “Recent reports have suggested that some of these reparative effects are mediated by paracrine factors secreted by MSCs (Caplan and Dennis, 2006a; Gnecchi et al., 2005, 2006; Schafer and Northoff, 2008).”
• Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. (2008, background): “Recently, it has been demonstrated that rat bone marrow derived MSCs, transduced with the survival gene Akt, can protect ischemic myocardium via their paracrine secretions (Gnecchi et al., 2005).”
• Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity (2009, background): “Many studies have failed to document MSC differentiation into cardiac cell constituents in the infarcted heart (12, 28, 29).”
• Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming (2012, neutral): “Because these transplanted populations do not generate new cardiomyocytes, the improvement may be due to paracrine effects that lead to enhanced vascularization (Gnecchi et al., 2005).”
• Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts (2007, background): “There is evidence that transplanted cells produce paracrine factors that enhance survival of host cardiomyocytes postinfarctio”
• Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. (2015, neutral): “(73) first proposed that the effect of genetically engineered MSCs takes place in less than 72 h, before any regeneration can take place, and showed that CM from MSCs (MSC-CM) cultured in vitro have efficacy comparable to that of whole-cell transplantation in preventing ventricular remodeling.”
• Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. (2013, background): “Most studies suggest that MSCs mediate their therapeutic efficacy through the secretion of paracrine factors (Chimenti et al., 2010; Gnecchi et al., 2005, 2006, 2008).”